Financials (USD)
Sales 2024 * | 72.54M | Sales 2025 * | 68.35M | Capitalization | 253M |
---|---|---|---|---|---|
Net income 2024 * | -168M | Net income 2025 * | -167M | EV / Sales 2024 * | 1.91 x |
Net cash position 2024 * | 115M | Net cash position 2025 * | 281M | EV / Sales 2025 * | -0.41 x |
P/E ratio 2024 * |
-1.63
x | P/E ratio 2025 * |
-2.06
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.18% |
Latest transcript on Nektar Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 71 | 06-12-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
Sandra Gardiner
DFI | Director of Finance/CFO | 58 | 23-04-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
R. Scott Greer
BRD | Director/Board Member | 65 | 09-12-31 |
Roy A. Whitfield
BRD | Director/Board Member | 70 | 00-07-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
1st Jan change | Capi. | |
---|---|---|
+25.61% | 660B | |
+25.87% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+7.09% | 219B | |
-9.12% | 196B | |
+5.01% | 199B | |
-8.75% | 149B |